InnoPharmax Inc.

NT$9.04As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4172Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (11.86%)
Div yield —
ROE (37.62%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) (0.02)
PE TTM —
TSR TTM (50.54%)
Mkt cap NT$1.081B
ROIC (21.64%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$11
23.22%
(80.46%)
Hold 12|12|4|10|0
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.15
0.16
0.17
0.17
10.81%
13.68%
12.90%
12.34%
RevenueNT$M
112.8
118.7
125.6
127.5
1.36%
9.48%
11.34%
11.05%
Peers (US$32.68M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.350
0.182
0.186
EBIT/Intx
0.282
0.153
0.152
Own earn%
(65.42)
(45.75)
(42.54)
Sh yield%
34.67
48.69
43.24
Owners
Insiders/Inst%
2.22
23.13
Short interest%
4.92
SBC / revenue%
4.27
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
4–9
$1 testx
0.7
Incr. ROIC%
7